Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery (Photostent-02)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University College, London
ClinicalTrials.gov Identifier:
NCT00513539
First received: August 6, 2007
Last updated: February 18, 2013
Last verified: February 2013
  Purpose

RATIONALE: Biliary stenting is the placement of a tube in the bile ducts to keep a blocked area open. Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. It is not yet known whether biliary stenting is more effective with or without photodynamic therapy in treating patients with biliary tract tumors.

PURPOSE: This randomized phase III trial is studying biliary stenting to see how well it works compared with biliary stenting and photodynamic therapy using porfimer sodium in treating patients with locally advanced, recurrent, or metastatic cholangiocarcinoma or other biliary tract tumors that cannot be removed by surgery.


Condition Intervention Phase
Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Drug: porfimer sodium
Procedure: biliary stenting
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study

Resource links provided by NLM:


Further study details as provided by University College, London:

Primary Outcome Measures:
  • Overall survival [ Time Frame: minimum follow up 3 years or until death ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-free survival every 3 months [ Time Frame: minimum follow up 3 years or until death ] [ Designated as safety issue: No ]
  • Toxicity as assessed by NCI CTC v. 3.0 [ Time Frame: patients followed up for minimum of 3 years ] [ Designated as safety issue: Yes ]
  • Quality of life as assessed by EORTC QLQ 30 and PAN 26 at baseline and 1, 3, and 6 months after completion of study treatment [ Time Frame: patients followed up for a minimum of 3 years ] [ Designated as safety issue: No ]

Enrollment: 92
Study Start Date: July 2007
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm A
Biliary Stenting alone
Procedure: biliary stenting
Experimental: Arm B
Photodynamic Therapy plus biliary stenting
Drug: porfimer sodium Procedure: biliary stenting

Detailed Description:

OBJECTIVES:

Primary

  • To assess the efficacy, in terms of overall survival, of biliary stenting with vs without photodynamic therapy using porfimer sodium in advanced, recurrent, or metastatic biliary tract carcinoma.

Secondary

  • To evaluate the two treatments arms with respect to progression-free survival, toxicity using NCI Common Toxicity Criteria (version 3.0), and quality of life.

OUTLINE: This is a multicenter study. Patients are stratified by participating center, primary site (gallbladder vs bile duct), disease stage (locally advanced vs metastatic), prior therapy (i.e., surgery, radiotherapy or chemotherapy) (yes vs no), performance score (0 vs 1 vs 2 vs 3), and prior treatment arm on UK chemotherapy trial ABC-02 (gemcitabine hydrochloride alone vs gemcitabine hydrochloride and cisplatin). Patients are randomized to 1 of 2 arms.

  • Arm I: Patients undergo either endoscopic or percutaneous drainage and insertion of unilateral or bilateral plastic endoprostheses above the main strictures of the right and left hepatic bile ducts.
  • Arm II: Patients undergo treatment as in arm I. Patients also receive porfimer sodium IV and then undergo laser activation 48 hours later.

After completion of study treatment, patients are followed every 3 months for at least 3 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

Inclusion criteria:

  • Histopathological/cytological diagnosis of nonresectable locally advanced, recurrent, or metastatic biliary tract carcinoma (intra- or extra-hepatic), or gallbladder carcinoma
  • Adequate biliary drainage, with no evidence of active uncontrolled infection (patients on antibiotics are eligible)

Exclusion criteria:

  • Porphyria
  • No brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

  • ECOG performance status 0, 1, 2, or 3
  • Estimated life expectancy > 3 months
  • Women of child-bearing potential should have a negative pregnancy test prior to study entry AND be using an adequate contraception method, which must be continued for 1 month after completion of treatment
  • Not pregnant or nursing

Exclusion criteria:

  • History of prior malignancy that will interfere with the response evaluation (exceptions include in-situ carcinoma of the cervix treated by cone-biopsy/resection, non-metastatic basal and/or squamous cell carcinomas of the skin, or any early stage (stage l) malignancy adequately resected for cure greater than 5 years previously)
  • Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial
  • Any psychiatric or other disorder likely to impact on informed consent

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

  • Patients may have undergone a non-curative operation (i.e., R2 resection [with macroscopic residual disease] or palliative bypass surgery only) and fully recovered

    • Patients who have previously undergone curative surgery must have evidence of non-resectable disease relapse
  • Patients may have received prior radiotherapy within the past 28 days (with or without radio-sensitizing low-dose chemotherapy) for localized disease and fully recovered

    • Must have clear evidence of disease progression prior to inclusion in this study
  • Patients may have received prior chemotherapy within the past 28 days and fully recovered

    • Must have clear evidence of disease progression prior to inclusion in this study

Exclusion criteria:

  • Previous treatment with curative intent for current disease in the last 12 weeks (i.e., prior resection, radical radiotherapy, or chemotherapy)
  • Previous treatment with experimental therapy for current disease in the last 12 weeks
  • No cytotoxic chemotherapy, radiotherapy, immunotherapy, hormonal therapy (excluding contraceptives and replacement steroids), or experimental medications will be permitted for the first four weeks of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00513539

Locations
United Kingdom
Aintree University Hospital
Liverpool, England, United Kingdom, L9 7AL
University College Hospital
London, England, United Kingdom, NW1 2PG
Queen's Medical Centre
Nottingham, England, United Kingdom, NG7 2UH
Ninewells Hospital
Dundee, Scotland, United Kingdom, DD1 9SY
Sponsors and Collaborators
University College, London
Investigators
Study Chair: Stephen P. Pereira, MD University College London Hospitals
  More Information

Additional Information:
No publications provided

Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT00513539     History of Changes
Other Study ID Numbers: CDR0000558540, CRUK-PHOTOSTENT-02, EU-20740, EUDRACT-2005-001173-96, ISRCTN87712758, CTA-20363/0207/001-0001
Study First Received: August 6, 2007
Last Updated: February 18, 2013
Health Authority: United Kingdom : Medicines and Healthcare Research Authority (MHRA)

Keywords provided by University College, London:
unresectable gallbladder cancer
recurrent gallbladder cancer
metastatic gallbladder cancer
cholangiocarcinoma of the gallbladder
unresectable extrahepatic bile duct cancer
recurrent extrahepatic bile duct cancer
metastatic extrahepatic bile duct cancer
cholangiocarcinoma of the extrahepatic bile duct

Additional relevant MeSH terms:
Gallbladder Neoplasms
Bile Duct Neoplasms
Cholangiocarcinoma
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Biliary Tract Diseases
Digestive System Diseases
Gallbladder Diseases
Bile Duct Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Trioxsalen
Dihematoporphyrin Ether
Photosensitizing Agents
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dermatologic Agents
Therapeutic Uses
Antineoplastic Agents

ClinicalTrials.gov processed this record on July 22, 2014